HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

ONCOFID-S

an antineoplastic agent; structure in first source

Networked: 2 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Alkaloids: 5398
  - Camptothecin: 2033
    - ONCOFID-S: 2
Carbohydrates: 22023
- Polysaccharides: 15383
  - Glycosaminoglycans: 5640
    - Hyaluronic Acid: 11384
      - ONCOFID-S: 2

Experts

1.	Campisi, Monica: 2 articles (01/2015 - 03/2012)
2.	Renier, Davide: 2 articles (01/2015 - 03/2012)
3.	Carpanese, Debora: 1 article (01/2015)
4.	Merlo, Anna: 1 article (01/2015)
5.	Montagner, Isabella Monia: 1 article (01/2015)
6.	Pasut, Gianfranco: 1 article (01/2015)
7.	Rosato, Antonio: 1 article (01/2015)
8.	Zanovello, Paola: 1 article (01/2015)
9.	Zuccolotto, Gaia: 1 article (01/2015)
10.	Bettella, Fabio: 1 article (03/2012)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2015 - "In vivo, the intraperitoneal administration of ONCOFID-S in tumor-bearing mice did not induce inflammation, and evidenced an improved therapeutic efficacy compared with CPT-11. "
2.	Inflammation (Inflammations) 01/01/2015 - "In vivo, the intraperitoneal administration of ONCOFID-S in tumor-bearing mice did not induce inflammation, and evidenced an improved therapeutic efficacy compared with CPT-11. "
3.	Carcinoma (Carcinomatosis) 01/01/2015 - "To this aim, the efficacy of a loco-regional intraperitoneal treatment with a bioconjugate (ONCOFID-S) derived by chemical linking of SN-38, the active metabolite of irinotecan (CPT-11), to hyaluronan was assessed in a mouse model of ovarian carcinomatosis. "
4.	Peritoneal Neoplasms 03/01/2012 - "This finding reinforces the rationale for developing Oncofid-S in the loco-regional intraperitoneal treatment of peritoneal carcinomatosis in man." 03/01/2012 - "In view of a possible clinical development for loco-regional treatment of peritoneal carcinomatosis, this study aimed to establish the pharmacokinetic profile of Oncofid-S after single intraperitoneal or intravenous administration in the rat. "

Related Drugs and Biologics

1.	Hyaluronic Acid (Hyaluronan)
2.	Irinotecan (Camptosar)

Related Therapies and Procedures

1.	Intravenous Administration